Alphamab Oncology Income Statement

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Operating Revenue	566.24	640.08	218.77	166.85	146.02
Revenue	566.24	640.08	218.77	166.85	146.02
Revenue Growth (YoY)	-11.54%	192.58%	31.12%	14.26%	-
Cost of Revenue	63.55	60.32	55.24	44.21	3.03
Gross Profit	502.69	579.77	163.54	122.64	142.99
Selling, General & Admin	83.82	75.11	79.56	86.94	77.55
Research & Development	572.16	403.65	407.3	468.07	481.06
Operating Expenses	655.98	478.76	486.86	555.01	558.61
Operating Income	-153.29	101.01	-323.33	-432.37	-415.62
Interest Expense	-7.45	-9.92	-12.18	-14.21	-13.18
Interest & Investment Income	-	49.26	74.04	33.87	27.81
Currency Exchange Gain (Loss)	-	13.45	33.19	66.71	-41.41
Other Non Operating Income (Expenses)	46.8	12.56	17.68	20.28	29.99
EBT Excluding Unusual Items	-113.94	166.34	-210.59	-325.72	-412.42
Pretax Income	-113.94	166.34	-210.59	-325.72	-412.42
Earnings From Continuing Operations	-113.94	166.34	-210.59	-325.72	-412.42
Net Income	-113.94	166.34	-210.59	-325.72	-412.42
Net Income to Common	-113.94	166.34	-210.59	-325.72	-412.42
Shares Outstanding (Basic)	949	962	960	937	935
Shares Outstanding (Diluted)	949	984	960	937	935
Shares Change (YoY)	-3.52%	2.53%	2.50%	0.11%	0.62%
EPS (Basic)	-0.12	0.17	-0.22	-0.35	-0.44
EPS (Diluted)	-0.12	0.17	-0.22	-0.35	-0.44
Free Cash Flow	-	190.56	-239.02	-429.96	-478.72
Free Cash Flow Per Share	-	0.19	-0.25	-0.46	-0.51
Gross Margin	88.78%	90.58%	74.75%	73.50%	97.93%
Operating Margin	-27.07%	15.78%	-147.79%	-259.14%	-284.63%
Profit Margin	-20.12%	25.99%	-96.26%	-195.22%	-282.44%
Free Cash Flow Margin	-	29.77%	-109.26%	-257.70%	-327.84%
EBITDA	-88.94	165.36	-267.54	-391.83	-387.1
EBITDA Margin	-15.71%	25.83%	-122.29%	-234.85%	-265.10%
D&A For EBITDA	64.35	64.35	55.78	40.54	28.52
EBIT	-153.29	101.01	-323.33	-432.37	-415.62
EBIT Margin	-27.07%	15.78%	-147.79%	-259.14%	-284.63%

Source: S&P Global Market Intelligence. Standard template. Financial Sources.